mediseen

Innovative research in healthcare

Presentazione dell' Azienda
Giugno 2024

mediseen

Innovative research in healthcare

La nostra azienda

Centro Strategico
Ricerca innovativa AI
Farmaci mancanti
Diagnostica
Terapia e Cura

Artificial Intelligence Publications

(PubMed Results by Year)



I nostri obiettivi

Ricerca

Impegnati per sostenere la ricerca e scoprire soluzioni innovative

Marketing

Sostenere le Aziende del Gruppo con progettualità innovative a beneficio di medici, pazienti ed ecosistema

Approvvigionamento

Aiutare Ospedali, Cliniche e gruppi d'acqiuisto ad assicurare le scelte terapeutiche ideali per i pazienti

Piattaforma AI

La prima piattaforma di gestione di approvvigionamento con un software di proprietà fondato su AI



Attività

01



Research

Partnership con Università
Istituti di ricercerca
Selezionate aziende innovative

02



Marketing

Investire sui migliori prodotti sostenuti da evidenze cliniche in ofta, derma ed alter aree con le aziende del network

03



Supply

Centro di riferimento per ospedali pubblici e privati

04



Piattaforma AI

web-based
proprietary algorithm
Gestione crisi farmaci mancanti

Team



Michelangelo Simonelli
Presidente



Marco Beni
Vice Presidente



Giuseppe V. Romano
Direttore Medico



Bruno Alek Vansy Houn
Board Member



Tiziana Zampieri
Board Member



Daniele Palmisani
Board Member

Group Companies Asset



KILABS

Ophthalmology

Si&Co.Pharma

Ophthalmology
Dermatology

Gruppo Ortodermico Laboratorio
40 anni di esperienza, tradizione e qualità

Trichology

Team

President & CEO
Michelangelo Simonelli



Head of Sales
Luciano Arfè



GM Derma
Alessandro Cappella



Medical Director
Giuseppe Romano, MD



Comex Head & i-CFO
Daniele Palmisani



03 Supply

Increasing drug shortage in the last two years



Data based on AIFA update of 31-Dec-2022. Analysis by Wired Italia

Ceased marketing of the product: about 58% of cases of shortage.
In all these cases, the product will no longer be made available by the company.



1.269 lacking drugs
for definitive marketing discontinuation

750 lacking drugs
for production problems

Data based on AIFA update of 31-Dec-2022.
Analysis by Wired Italia

For a large part of the medicines in short supply, there is no equivalent. Without an equivalent, the only possibility is importing from reliable partners



169 unavailable drugs for definitive marketing discontinuation don't have any equivalent

137 lacking drugs for production problems don't have any equivalent.

The numbers represent the drugs in shortage without equivalent divided by the reason for the shortage reported by AIFA.
Data based on AIFA update of 31-Dec-2022. Analysis by Wired Italia.

The MEDISEEN commitment:

At the service of the hospitals and purchasing groups to facilitate the availability of medicines that are lacking or difficult to find, professionally and with promptness



* Feedback collected from contacts with 16 hospitals and purchasing centres on the problem of medicine shortages

04

AI Hub

Scenario

The EU’s endless drug shortage is the result of fragile supply chains

1. Materials are sourced from every corner of the globe
2. Distribution is 'just in time' to keep costs low
3. Production is in a few highly specialised factories.

As result, stocks of medicines tend to be non-existent because producers, governments and healthcare providers are not willing to pay the costs of inventory.

Under all these said pressure Pharma Companies tend to manage distribution by optimising the margin.

AN UP-TO DATE HUB BACKED BY AI AND AN AD-HOC ALGORITHM WHERE SUPPLY AND DEMAND CAN MEET IS A CRUCIAL CONTRIBUTION IN THIS SCENARIO

Solution

A revolutionary high-frequency B2B online scientific market hub powered by AI with high strategic value capable of managing the European and global crisis in the shortage of medicines

it is based on a high-tech proprietary algorithms with the ability to manage the global supply chain.

It is mainly based on public informations already available but not structured in a dedicated hub

About the Project

The Mediseen platform is capable of:

- Efficiently managing an entire production, supply, marketing, and distribution chain of goods and services through the definition of complex management methodologies;
- Coordinating the activities of production, purchasing, and logistics;
- Generating production forecasts and market trends;
- Developing purchasing and production plans through the "supply chain planning system," and enabling the coordination and control of product flows in warehouses and various distribution centers worldwide through the "supply chain execution system";
- Realizing intelligent mapping of existing products and molecules and their availability by geographic areas;
- Monitoring market KPIs to identify weak links in the chain to optimize;
- Standardizing processes and integrating the platform with all the IT solutions dedicated to the scientific sector.



Thanks

Please Contact us

michelangelo.simonelli@mediseen.it
+39 366 608 7732
www.mediseen.it